BERKELEY, CA USA (UroToday.com) - Over the past few years, a number of new and promising treatments have emerged to improve survival in patients whose prostate cancer is not responsive to traditional androgen deprivation therapy (ADT).
Clinical decision-making for patients with metastatic castration-resistant prostate cancer (mCRPC) is complex, not only because of the multiple options available for treatment, but also due to the necessity of proper sequencing of these medications in patients.
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
E. David Crawford is an internationally recognized urologist and is the distinguished endowed professor of surgery, urology, and radiation oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. He also serves as the practice director for the urologic oncology clinic. His areas of expertise include benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer.
Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship, at the University of California Medical Center, in Los Angeles.
The recipient of more than 95 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 450 articles that have been published in such journals as Urology, the New England Journal of Medicine, the Journal of Urology, and the Journal of the National Cancer Institute. He has published five textbooks and authored over 50 book chapters, and is an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, the New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology.
Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science. He served as the Chairman of the Genitourinary Cancer Committee of the Southwest Oncology Group for 28 years. He is also the Founder and Chairman of the Prostate Conditions Education Council which is responsible for screening nearly four million men for prostate health issues and reaches more than 200 million people each year with education and awareness information. Dr. Crawford's involvement in the national prostate cancer arena has been widely recognized and he has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a “Freddie Award” at the AMA International Health and Medical Film Competition for the program ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Dr. Crawford hosted with special guest retired General Norman Schwarzkopf. He, again, won a prestigious “Freddie Award” in 2005. He has been recognized as one of the Best Doctors of America for the past decade, and Best Cancer Doctors. Recently, he was awarded the honor of being selected as the Best Healthcare Provider in the Denver Metro area by the Denver Business Journal, Blue Cross, and Anthem Healthcare. He is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine.